Deal-happy Roche acquires Trophos
This article was originally published in Scrip
In yet another deal, Roche is acquiring rare disease drug developer Trophos at a price of €120m upfront, and a further €350m in potential milestone payments.
You may also be interested in...
Problems over formulation and the arrival of effective treatment options in spinal muscular atrophy, headed by Biogen's antisense oligonucleotide drug Spinraza, have led to the plug being pulled on olesoxime - but the Swiss major has a back-up candidate.
Initial VC and institutional funding from a French syndicate will support further drug development at Paris-based Horama, which aims to put two targeted gene therapies for hereditary retinitis pigmentosa in the clinic by 2018.
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.